SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
Yutaka Okawa(Jikei University School of Medicine), Kenneth C. Anderson(Novartis (Switzerland))
Cited by 208
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
|Blood|2002|667
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
|Proceedings of the National Academy of Sciences|2005|596